Forskolin

Catalog No.S2449 Synonyms: Coleonol

Forskolin Chemical Structure

Molecular Weight(MW): 410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 270 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 18 Publications

6 Customer Reviews

  • Relative NPY and IL6 expression in Myc-CaP cells treated with NE or forskolin for 6 hours, or treated with the β2AR blocker ICI118551 2 hours before NE in the presence of ICI118551 for 6 hours (n ¼ 4)

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-2912. Forskolin purchased from Selleck.

    Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

  • T24 cells were treated with IFN-α (1 × 104 U/mL), TPL2i (2 μM), PD98059 (40 μM), or forskolin (50 μM) for 24 h. The expression levels of COX-2, CREB, and p-CREB were analyzed by western blotting. The β-tubulin was used as the loading control.

    J Exp Clin Cancer Res, 2019, 37(1):288. Forskolin purchased from Selleck.

    Western blot analysis shows pERK levels after 8 hours treatment with forskolin. AC activation with 10 μmol/L forskolin (F).

    Mol Cancer Res, 2017, 15(12):1792-1802. Forskolin purchased from Selleck.

  • The pH-dependent regulation of the nucleo-cytoplasmic translocation of YAP and phosphorylation of YAP was regulated by Forskolin and H 89 2HCl, as assessed by western blotting.

    Sci Rep, 2016, 6:26835. Forskolin purchased from Selleck.

    Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

Purity & Quality Control

Choose Selective cAMP Inhibitors

Biological Activity

Description Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
Targets
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
In vitro

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MYPGeY5kfGmxbjDBd5NigQ>? MX6xNEDPxE1? M{W4b|YhcA>? M3rlOYlv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4Yhd3[ncnX4dJJme3OnZDDLUGhNOyCjdDDTOFM{ MlWxNlY1OzV2OUi=
Mo-DCs MVLGeY5kfGmxbjDBd5NigQ>? MUm1NEDPxE1? MorlNlTjiImq MWDwdo9ud3SnczDJUE0zOyCycn;keYN1cW:wIHnuJJRp\SC|dYDldo5ifGGwdDDv[kB7gW2xc3HuJJN1cW23bHH0[YQhVW9vRFPzxsA> MkC2NlY1OTJ7NEi=
RBMECs  NHLRXldHfW6ldHnvckBCe3OjeR?= NUS0Tmo1PcLizszN MmDmNeKhcA>? NWrGVXN{[myxY3vzJJRp\SCUYXOxJIlv[WO2aY\heIlwdiCrbnT1Z4VlKGK7IFXNRXAuUUl? NIDYT3IzPjN3OECzPS=>
INA-6 M17BXGNmdGxiVnnhZoltcXS7IFHzd4F6 NI\u[WcxNTFyMDFOwG0> MoLFO|LjiImq NEPQXGlqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NInkSFMzPjNyNk[yOC=>
OPM-2 NIC2co5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVewMVExOCEQvF2= M2HkNFcz6oDLaB?= MmXSbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= MV[yOlMxPjZ{NB?=
U266 M2XjT2NmdGxiVnnhZoltcXS7IFHzd4F6 M{LZb|AuOTByIN88US=> M130NVcz6oDLaB?= M4PLNYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 M1XSclI3OzB4NkK0
H929 MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlzuNE0yODBizszN MYi3NwKBkWh? MkfvbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NWDHco0xOjZ|ME[2NlQ>
RPMI 8226 MnnZR4VtdCCYaXHibYxqfHliQYPzZZk> MlT2NE0yODBizszN NFK0PVE4OuLCiXi= MmjybY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= M1r6XFI3OzB4NkK0
MDCK  NUXYXXVHTnWwY4Tpc44hSXO|YYm= M1rVeFExKML3TR?= MXeyOEBp NX7X[Go2TE2VTx?= NU\JR2FnfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiVFfGMe6zOSCjbnSgR3RITsLi NV2wdG55OjZ{MEKzOVI>
MDCK  MoXHSpVv[3Srb36gRZN{[Xl? MmPjNVAhyrWP MmD6NlQhcA>? M2DuTWROW09? M4T2folvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? MWGyOlIxOjN3Mh?=
Spinal cords  NGjnNVRHfW6ldHnvckBCe3OjeR?= NYrJPVRZOcLizszN NYHpNVJKOzBibXnu M3XzWJN1cW23bHH0[ZMh[0GPUDDs[ZZmdHN? MV6yOlEzPjl{Nh?=
BeWo  M3\XcWZ2dmO2aX;uJGF{e2G7 M4P4V|I26oDLzszN MV[yOE81QC95MjDo NFjS[WZt\WGmczD0c{BidiCrbnPy[YF{\SCrbjD0bIUh\XiycnXzd4lwdiCxZjDveIhmeiCodYPpc44hdWG{a3Xydy=> MVWyOlA2OzV2OR?=
bovine oocytes M4DZcmZ2dmO2aX;uJGF{e2G7 MVmxNFDDqM7:TR?= MkfzNVLDqGh? NX\ublhbcW6qaXLpeJMhfGinIHXm[oVkfCCxZjDOVHBCKGGwZD;vdkBPWFCFIITvJJN1cW23bHH0[UBz\XO3bYD0bY9vKG:oIH3lbY9{cXN? MYiyOlA2OTZzMR?=
Caco-2  MXzGeY5kfGmxbjDBd5NigQ>? NHTvTI4xNjFxMT:xNEDPxE1? MoHINlDDqG2rbh?= NYjPVGw2cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ2FOWCCuZY\lcJM> NHi5NHgzPjB2OUGwNi=>
Caco-2  M3\Nd2Z2dmO2aX;uJGF{e2G7 M135N|AvOS9zL{GwJO69VQ>? MonINlQhcA>? MnfwbY5kemWjc3XzJG1TWDJicILveIVqdiCuZY\lcC=> NUfEcVI4OjZyNEmxNFI>
AML-12  NHu3ZlRHfW6ldHnvckBCe3OjeR?= NX7wbINQOjBizszN NV;vbIhCOyCq M1TWR5VxemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ibHX2[Yx{KGG2IGTodk01OTFiYX7kJHNmei12OUO= M1nheVI3ODR6OUi1
AML-12  NGXSTGFHfW6ldHnvckBCe3OjeR?= MlKzNlAh|ryP MnLZNU05KGh? NVrJOI0{cW6lcnXhd4V{KGeudXPvd4UheHKxZIXjeIlwdg>? M3n1RVI3ODR6OUi1
AML-12  NXmwPXBnTnWwY4Tpc44hSXO|YYm= Mk[wNlAh|ryP MYizJIg> M4OxPJVxNXKnZ4XsZZRme8LiUHfjNYEtyqCSZYDjb{wh[W6mwrDHOpBkyqCvUl7BJIxmfmWucx?= MoPKNlYxPDh7OEW=
AML-12  NWnDOXN3TnWwY4Tpc44hSXO|YYm= M1XyflIxKM7:TR?= MVWzJIg> MXHpcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBw\iCFUmTDNuKh Mkj4NlYxPDh7OEW=
RBMECs M2XLSGZ2dmO2aX;uJGF{e2G7 M4WyXlXDqM7:TR?= NX3YTodROSCq NU[1XlFscW6qaXLpeJMhTU2DUD3JTU1qdmS3Y3XkJIlv[WO2aY\heIlwdiCxZjDSZZAyyqB? NWfpRWI1OjZyNES2OlM>
EndoC-βH1 MUHGeY5kfGmxbjDBd5NigQ>? Mn;COeKh|ryP MXGxJIg> M363WZBwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> Mn3KNlYxOjh3NkK=
EndoC-βH1 Mn;TSpVv[3Srb36gRZN{[Xl? M1zLdFXDqM7:TR?= NW\VWIh7OSCq NWfsWFVydGWjZIOgeI8h[SC|dILvcoch[0GPUDDpcoNz\WG|ZR?= M3fzSVI3ODJ6NU[y
SH-SY5Y MkD1SpVv[3Srb36gRZN{[Xl? MWKzNEDPxE1? NIjnbVM{OCCvaX6= M37kfGROW09? NG\pWFJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUh[WO2aY\heIlwdiCxZjDQT2E> MU[yOlAzPTF|Nx?=
PC-3 MY\GeY5kfGmxbjDBd5NigQ>? MXq0NEDDvU1? M2\rPFIhcA>? MlL3SG1UVw>? NYnqbldUdGWjZIOgeI8hWFB{QTDhZ5RqfmG2aX;u MWGyOlAzOzh|Nh?=
PC-3 NFrxeZBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUPrVHlUPDBiwsXN NF3ncJozPC92OD:3NkBp M{jNeGROW09? NH\tWoZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= NFT0V3czPjB{M{izOi=>
SCG M4TJXWZ2dmO2aX;uJGF{e2G7 MVGyNEDPxE4EoB?= M3y0d2ROW09? M{nnV5JmfmW{c3nicJkhe3WycILld5NmeyCLS2[ge4l1cCCjIFnDOVAhd2ZiMkSuOEDPxE1? NE\jWXQzPTl4MkGzNi=>
HEK-293 NYfqXIk5TnWwY4Tpc44hSXO|YYm= M{HKOFM2KM7:TdMg MYXEUXNQ NGXUT2pqdmS3Y3XzJIEh[2:wc4DpZ5VwfXNi4pEcbY5i[3SrdnH0bY9v6oDfIH;mJJRp\SCNdkKuNUBkfXK{ZX70 NF7McW4zPTl4MkGzNi=>
SCG MXHGeY5kfGmxbjDBd5NigQ>? NUL6cVFGOTByIN88UeKh MVvEUXNQ NWXu[m8{emWmdXPld{B1cGViZYjjbZRi[mmuaYT5JI9nKFOFRzDu[ZVzd26| NEG5U|EzPTl4MkGzNi=>
PCCL3 MmftSpVv[3Srb36gRZN{[Xl? NIr6d2UyOCEEtV2= MmrmNlQhcA>? NEHpOXNmdmijbnPld{BFfU:6MjDwdo9ud3SncjD0doFve2O{aYD0bY9vKGGldHn2bZR6yqEkgJu= NYjTVXplOjV7NkC5OVY>
3T3-L1 preadipocytes NWXpfINXTnWwY4Tpc44hSXO|YYm= M1nXN|ExKM7:TdMg Mn\2NVIhcA>? MWrpcoR2[2W|IFPSSWIheGixc4Doc5J6dGG2aX;uJIFv\CCFL1XCVO6zKGW6cILld5Nqd25? M3XKflI2QTJ6MEW4
H295R  NGLMdXBHfW6ldHnvckBCe3OjeR?= M{jnV|ExyqEQvF2= NH7OOGY1QMLiaB?= NYjNc4tncW6lcnXhd4V{KHO2ZYLvbYQhdWW2YXLvcIl1\XNiaX6geIhmKGGwZILv[4VvNCCvaX7ldoFtdy1iYX7kJIdtfWOxY3;yeIlkd2mmIIDheIh4[Xm| Mnu0NlU5Pjl3NU[=
PBMC NUPu[GVVTnWwY4Tpc44hSXO|YYm= Ml7VOVDDqM7:TR?= MorHNlTDqGkEoB?= MX7pcohq[mm2czD0bIUhcW6lcnXhd4VlKHOnY4LleIlwdiCxZjDUUmYhcW6mdXPl[EBjgSC2aHWgSHBG MlvrNlU5PjZyN{m=
GLUTag  MX\GeY5kfGmxbjDBd5NigQ>? M1\TRlEx6oDLwsXN MmrONE8zNzRiaB?= M33TSJN1cW23bHH0[ZMhT0ySLUGgd4VkemW2aX;uJINwfHKnYYTl[EB4cXSqIFnCUXg> M1;WclI2QDN{NkOx
GLUTag  M4G3ZmZ2dmO2aX;uJGF{e2G7 MmfmNVDjiIoEtV2= MWK0JIg> MnP1bY5kemWjc3XzJJRp\SCyQ2LFRkBt\X[nbIOge4l1cCC2aHWgTWJOYA>? NIHQ[3MzPTh|Mk[zNS=>
BAECs M3LlN2Z2dmO2aX;uJGF{e2G7 M4m2TVI2KM7:TR?= Ml\TNlQhcA>? M1jZSIVvcGGwY3XzJJRp\SCjY4TpeoF1cW:wIH;mJHBRSVMQsTDifUA2KM7:TTDy[ZN3\XKjdILvcEwhXDSKUzygc5IhPC2SQWC= M13oV|I2Pzl6OEK2
PC12 M33BNmZ2dmO2aX;uJGF{e2G7 MUSyOeKh|ryP MlPZOFghcA>? MXPhZ5RqfmG2ZYOgZ2FOWA>? NXLJe2x5OjV5NkmzNFU>
GH3 NHfmPJJHfW6ldHnvckBCe3OjeR?= NGLETZIyyqEQvF2= MXq2MYg> NUT4WJN7[XS2ZX71ZZRmeyC2aHWgZ49zemWuYYTpc44h[mW2d3XlckBRWkxiYX7kJGJu[WxzIHX4dJJme3Orb36= NWi1fIJjOjV5MkewNVg>
GH3 MkfPSpVv[3Srb36gRZN{[Xl? NFfWeGwyyqEQvF2= NVrzbG9ZPi2q MW\pcoR2[2W|IGDSUEBidmRiQn3hcFEtKGK3dDDuc5QhS2yxY3usJI1TVkFiZYjwdoV{e2mxbh?= NEj0OnIzPTd{N{CxPC=>
BeWo M{DpXmZ2dmO2aX;uJGF{e2G7 MV:xNQKBks7:TdMg NIn1b2Y4OiCq M4PTd2ROW09? M{DpVo1m\GmjdHXzJGJmX29iY3XscEBlcW[oZYLlcpRq[XSrb36= MnjvNlU4OTN2MkW=
oocytes MUDGeY5kfGmxbjDBd5NigQ>? M17D[lUh|ryP MkXqNlQhcA>? MVfheJRmdnWjdHXzJJJpNWmwc4XsbY4h[WO2aX;uJI9vKG:xY4n0[UBIXkKGIIPp[45q\mmlYX70cJnDqA>? MWSyOVcxPzh3NB?=
SC Mn;lSpVv[3Srb36gRZN{[Xl? NVe5T5pxOC53IN88US=> M3uwfVI1KGh? M3vyNo1qdWmla4OgeIhmKGWoZnXjeEBw\iClQV3QJIFv[WyxZ4Ogc44hVzFiYX7kJG1DWCCneIDy[ZN{cW:w M2frblI2PzB3OEe0
SC NULXT5BWTnWwY4Tpc44hSXO|YYm= MljsNE42KM7:TR?= MnPNO|IhcA>? MXPpcoNz\WG|ZYOgZo91cCCNcn;4MVIxKGGwZDDPNUBmgHC{ZYPzbY9vKGmwIHH4c44uemWuYYTl[EBUS3NiYoX0JI9vdHliS4LvfE0zOMLi NULlNZhWOjV5MEW4O|Q>
UACC-647  MVLGeY5kfGmxbjDBd5NigQ>? NEnSNVNFVVOR MoDkcIVi\HNidH:gZUBzcXOnIHnuJINCVVBibHX2[Yx{KCiHQ{WwxsA:yqB{MD6zPeKh|ryPKR?= M{nDWlI2PzB|MEK1
UACC-647  NGfUc3pHfW6ldHnvckBCe3OjeR?= Mkj0NVDDqM7:TR?= MWixOUBucW5? NI\wenFFVVOR NX;UVJZycW6qaXLpeJMhTVKNIIDoc5NxcG:{eXzheIlwdg>? NUPjV2l4OjV5MEOwNlU>
UACC-647  NFrBb5ZHfW6ldHnvckBCe3OjeR?= MWOxNOKh|ryP NFfM[|MyPSCvaX6= NVHENnA2TE2VTx?= Mn7ubY5kemWjc3XzJIVGTjJicHjvd5Bpd3K7bHH0bY9vKGyndnXsd:Kh MYqyOVcxOzB{NR?=
SH-SY5Y  MlTYSpVv[3Srb36gRZN{[Xl? M4j6XVExyqEQvF2= M1jLfVHDqGkEoB?= MlSzbY5kemWjc3XzJGxWSyCjY4Tpeol1gQ>? M4LjOVI2PTl5NEOz
SH-SY5Y  NH;TbGdHfW6ldHnvckBCe3OjeR?= M1LmPFExyqEQvF2= M4n5UVHDqGkEoB?= MXTpcoNz\WG|ZYOgRWdEOSCvUl7BJIxmfmWu M4rWdFI2PTl5NEOz
hADSCs MkXTSpVv[3Srb36gRZN{[Xl? NFe0dpQ26oDLwsXN M4LCflMxKG2rbh?= NHqyU2ZqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? M1;ie|I2PTlzOUC4
HEK293  NVmw[ohxTnWwY4Tpc44hSXO|YYm= NIqwb5I26oDLwsXN M{fXWlMxKG2rbh?= NHO1TohqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? NWXIcVYzOjV3OUG5NFg>
3T3-L1 MoTWSpVv[3Srb36gRZN{[Xl? NFfldGszNjVxNTFOwG0> MVOyOEBpyqB? MlrBd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiQWTHUEBxem:2ZXnuJIV5eHKnc4Ppc44h[XRiYXzsJIRwe2W|IITld5Rm\A>? NFXSNFIzPTV7MEW5Oy=>
OCI-Ly1  M{X6Z2Z2dmO2aX;uJGF{e2G7 NIrScGQ1OMLizszN M2\MTFHDqGkEoB?= NVzncpBbTE2VTx?= NIDLWJZqdmS3Y3XzJJRp\SCrbnPy[Y1mdnRib3[gZ2FOWCClb37j[Y51emG2aX;udy=> M1W4eVI2PTd4MkKw
OCI-Ly18  NH;SZZZHfW6ldHnvckBCe3OjeR?= MlfDOFDDqM7:TR?= MXSxxsBpyqB? MmXWSG1UVw>? MoPJbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= MXOyOVU4PjJ{MB?=
BeWo NIricpRHfW6ldHnvckBCe3OjeR?= M2[xVVIxyqEEtV2= NWrUSpdxPDkEoHi= NFXhd2hFVVOR NHHmbGJqdmO{ZXHz[ZMhfGinIHTp[oZmemWwdHnheIlwdiCxZjDC[XdwKGOnbHzz NFnOXpEzPTV4Nke0NC=>
BeWo MWfGeY5kfGmxbjDBd5NigQ>? M3T6WFIxyqEEtV2= MV[0POKhcA>? MlzhSG1UVw>? MljWbY5kemWjc3XzJJRp\SCjZHjld4lwdiCxZjDUTHAuOSCvb37vZ5l1\XN? MljxNlU2PjZ5NEC=
LNCaP  MXLGeY5kfGmxbjDBd5NigQ>? MX[xNOKh|ryP NHHTPGYyOiCqwrC= MW\EUXNQ M4rITolv\HWlZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBw\iCFUlXCNUBi[3Srdnn0fS=> MU[yOVU1QDB7OR?=
ThGCs  NE\XVYFHfW6ldHnvckBCe3OjeR?= MXuxNQKBks7:TR?= M{XKflTjiIqq NUTqV2xF[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy NEDLOXczPTR|M{CyOy=>
ThGCs  NH\uR4dHfW6ldHnvckBCe3OjeR?= NIDjbIEyOOLCit88US=> MWC05qCLcA>? NEL1W2lqdmO{ZXHz[ZMhS2:FbEKtbY5lfWOnZDDFSG4zyqCpZX7lJIV5eHKnc4Ppc44> NXPaZ|R2OjV2M{OwNlc>
ThGCs  MnP0SpVv[3Srb36gRZN{[Xl? M{LJXVEx6oDMzszN M1rDZ|MhcA>? NUS3NGVncW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= NWrFUWVROjV2M{OwNlc>
RBMECs M37Y[WZ2dmO2aX;uJGF{e2G7 M3vDe|AvODVxMD61M|Uh|ryP M1r5S|AvOjViaB?= MVPpcoNz\WG|ZYOgZ2FOWCClb37j[Y51emG2aX;u M{fH[FI2PDF4NkWx
RBMECs NUDD[Fd4TnWwY4Tpc44hSXO|YYm= NVGweI16PcLizszN MVWxJIg> MYDicI9kc3NidHjlJIFkfGm4YYTpc44hd2ZiUnjvRU9TV0ONIHnu[JVk\WRiYomgSW1CWC2LSR?= NHzUfJQzPTRzNk[1NS=>
RBMECs NXTPVlRnTnWwY4Tpc44hSXO|YYm= MV21xsDPxE1? M3zvfFEhcA>? NV;3bJQ1eHKndnXueJMhfGinIFXNRXAuUUlvaX7keYNm\CCWRVXSJJZidHWnIHTlZ5Jm[XOn MX6yOVQyPjZ3MR?=
RBMECs M3mxRmZ2dmO2aX;uJGF{e2G7 NUDCVY9FPcLizszN M3jMSVEhcA>? MlnYdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIFjSVEBndHW6IHHjdo9{eyC2aHWgRnRDKGmwZIXj[YQh[nliIFXNRXAuUUl? NHf1OWgzPTRzNk[1NS=>
RBMECs NGP3d5RHfW6ldHnvckBCe3OjeR?= NGrubGk2yqEQvF2= NVvMPVl3OSCq NXHSfFYzcW6qaXLpeJMhfGinIHTlZ5Jm[XOnZDDv[kBidW:3boSgc4YhYk9vMTDpckBOTnNiaX7keYNm\CCkeTDFUWFRNUmL NF3XN24zPTRzNk[1NS=>
RBMECs MmrESpVv[3Srb36gRZN{[Xl? M3[xe|XDqM7:TR?= NH;1RoMyKGh? MoPjdoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 M{XhUlI2PDF4NkWx
RBMECs MlzSSpVv[3Srb36gRZN{[Xl? NYrTOnhqPcLizszN NUjyZodlOSCq MlLKZoxw[2u|IITo[UBGVUGSLVnJMYlv\HWlZXSgZ4hidmenIHnuJG1NSyCyaH;zdIhwenmuYYTpc44> NVXuRlk3OjV2MU[2OVE>
RBMECs MYjGeY5kfGmxbjDBd5NigQ>? NFr1O4M2yqEQvF2= Mn\YNUBp M17lWYJtd2OtczD0bIUh[WO2aX6gZ5l1d3OtZXzleI9vKHKnYYLyZY5o\W2nboSgd4VmdiC5aYToJGVOSVBvSVmgeJJm[XSvZX70xsA> NEG5NlQzPTRzNk[1NS=>
Primary bovine chondrocytes NHTSOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\UfI42|ryP M4rsUFQ5KGh? MoPrdoV3\XK|ZYOgeIhmKGmwaHnibZRwenliZX\m[YN1KG:oIHPlcIVkd3irYjDvckBxem:uaX\ldoF1cW:wIHnuJIdzd3e2aDDwcIF1\SClaH;u[JJw[3m2ZYO= MkfwNlU1ODZyMU[=
EM1  NXPpR|NtTnWwY4Tpc44hSXO|YYm= NX:3ZWQ5OTYkgJtOwG0> M{nD[lQ5KGh? MUTy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:owrDMTWbDqG:{wrDQWGdUOsLiaX9CpGNCVFJvIH;yxsBGWEGFMj3zbYxmdmOnZDDFUVEh[2WubIRCpC=> M1e0fVI2Ozd6Nk[x
BeWo  MVTGeY5kfGmxbjDBd5NigQ>? NHLDUGozOMLiwsXN NE\BboM1QMLiaNMg NV3hToNVTE2VT9Mg MYfpcoNz\WG|ZYOgeIhmKGKndHGtbGNIKHKnbHXhd4U> NFrxbG8zPTN4MkK2NC=>
BeWo  MYDGeY5kfGmxbjDBd5NigQ>? NYOw[Wt[OjEEoNM1US=> NYLYR|lUPDkEoHlCpC=> NFjJVnJFVVORwrC= NG\PNIVld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 M1vROlI2OzZ{Mk[w
BeWo  NWLGW|M5TnWwY4Tpc44hSXO|YYm= MWOyNOKhyrWP NIfDc|g1QMLiaNMg MnnLSG1UV8Li MlG0[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wxib3[gS2NONTF? Mn;nNlU{PjJ{NkC=
granulosa cells M36xOWZ2dmO2aX;uJGF{e2G7 NHrXPWYyOCEQvF2= NVTCXmdkOTJxMkSgbC=> NFjLUoNqdmO{ZXHz[ZMhfGinIHzleoVteyCxZtMgVmdUOsLibWLORS=> NGHQOYUzPTN|OUGwOS=>
granulosa cells M1PkRmZ2dmO2aX;uJGF{e2G7 M3rMelExKM7:TR?= MXmxNk8zPCCq NXvUS|M5cW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gdoVxd3K2ZYKgZYN1cX[rdImg[o9zKHSqZTDsc45o\XO2IH\yZYdu\W62IDlijLI5PTRxK{G4VmdUOi6OVVOp NH\VWngzPTN|OUGwOS=>
granulosa cells MVjGeY5kfGmxbjDBd5NigQ>? NWT5SGhlOTBizszN Ml\rNlQhcA>? NGPrXIhqdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kBFVkFxcILveIVqdiClb33wcIV5 M{X5b|I2OzN7MUC1
granulosa cells NYPCS3FVTnWwY4Tpc44hSXO|YYm= MnH6NVAh|ryP NYnEcWVLOjRiaB?= MoTnbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUlfTNkBxem:vb4TldkBi[3Srdnn0fS=> MYeyOVM{QTFyNR?=
SK-N-AS  M1HZd2NmdGxiVnnhZoltcXS7IFHzd4F6 MUOxNEDPxE4EoB?= MUWyOE81QCCq MXnlcohidmOnczD0bY1mNWSncHXu[IVvfGy7IHPlcIx2dGG{II\pZYJqdGm2edMg MoTjNlUzPjZyNkO=
SK-N-AS  NXj4d41UTnWwY4Tpc44hSXO|YYm= M4\wblExKM7:TdMg NHnObVMzPCCq NX;ZelcycW6lcnXhd4V{KHSqZTDjRW1RKGyndnXsd:Kh MmfLNlUzPjZyNkO=
SK-N-AS  MYTGeY5kfGmxbjDBd5NigQ>? NFP2RY8yOCEQvF5CpC=> MUiyOEBp MljIbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIN6[2yrbjDENS=> M3jzcFI2OjZ4ME[z
SK-N-AS  MX\GeY5kfGmxbjDBd5NigQ>? MlLQNVAh|ryPwrC= NXPTcGFOOzBibXnu MVzpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw M{Cw[VI2OjZ4ME[z
SK-N-AS  MoXCSpVv[3Srb36gRZN{[Xl? M3izTVExKM7:TdMg NX;tTIFkOTBxM{CvOlAhdWmw Mke5bY5kemWjc3XzJIxmfmWuczDv[kBxNc7{LXPheIVvcW5iKIPldlY4PSliYX7kJIlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIICt{tIu[2G2ZX7pckApe2W{Nke1LUBqdiBqcHXybUlvfWOuZXHyJJJm\2mxboO= M4rVUFI2OjZ4ME[z
SK-N-SH NH7sSYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV[xNEDPxE4EoB?= MXG0PEBp MVzlcohidmOnczDTT{1PNVOKIH7leZJw[myjc4TvcYEh[2WubDD2bYFjcWyrdIm= MlXSNlUzPjZyNkO=
HEK‐CFTR Mo\pSpVv[3Srb36gRZN{[Xl? MUSy5qCUPTEEoN88US=> MmXwNE0yOiCvaX6= Mo\ySG1UV8Li Moe4bY5lfWOnczDhJIRwe2YkgKDk[ZBmdmSnboSgbY9lcWSnIHXm[ox2gMLi MlnmNlUzPjN{MEe=
L6 NHLRdmxHfW6ldHnvckBCe3OjeR?= NVG0ZWpmPDBiwsXN NWS0W3I4OjRiaB?= NHSwdoRqdmirYnn0d{BFVUhzLXnu[JVk\WRiQXv0JIFkfGm4YYTpc44> NHLsdJczPTJ2N{W1NC=>
MIN6  MUTGeY5kfGmxbjDBd5NigQ>? NEfYToEyOCEQvF5CpC=> NWrVOZpmOyCq MVfpcoNz\WG|ZYOgSFMhdVKQQTDlfJBz\XO|aX;u M1m2TVI2OjRzMUK0
ventricular cardiomyocytes  NXq2XWFMTnWwY4Tpc44hSXO|YYm= NHvSdJAxNjBzLUGwJO69VQ>? MUDpcoNz\WG|ZYOgJINCVVBiYXPjeY12dGG2aX;u MWmyOVIxOzFzMx?=
ventricular cardiomyocytes  NXnIS5E2TnWwY4Tpc44hSXO|YYm= M2fieVAvODFvMUCg{txO MXnleo9s\XNiYX6gbY5wfHKxcHnjJJJme3CxboPlJFEzOMLzMUWlJIFjd3[nIHLhd4FtKHerdHigZY4hTUN3MNMgc4YhOi5{INM1US=> MW[yOVIxOzFzMx?=
BeWo  NWXZVYd7TnWwY4Tpc44hSXO|YYm= NF63PXozOCEEtV2= NIPIZpM1QCCq NXj5fI14TE2VT9Mg MkP5bY5lfWOnczDj[YxtKG[3c3nvci=> Mly4NlUyQDR2N{e=
THP-1  NF7VbXdHfW6ldHnvckBCe3OjeR?= NVTMW4dGOS9zMDFOwG0> MkHRNuKhcA>? NYnVPVduTE2VT9Mg NXfmd4lPe3WycILld5NmeyCPQ2CtNUBxem:mdXP0bY9vyqB? MkmyNlUyPTR6OEK=
Huh-7 M{\2OWZ2dmO2aX;uJGF{e2G7 NXLCR2V3OC1{MDFOwG0> NICwOlAzKGkEoB?= M1\ldpJme3WudIOgbY4h[SCmb4PlMYRmeGWwZHXueEBqdmO{ZXHz[UBqdiClLV35Z{BmgHC{ZYPzbY9vKGG2IITo[UBxem:2ZXnuJIFv\CCvUl7BJIxmfmWucx?= MknLNlUyODl6M{S=
C6 NUm1UWhGTnWwY4Tpc44hSXO|YYm= MlHLNVAh|ryPwrC= NIjTRXczOCCvaX6= NH7OSHRqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> MonLNlUxPjl2MUe=
SW480 NFKySWlHfW6ldHnvckBCe3OjeR?= MnfnOFDDqM7:TR?= MlvqOFjDqGh? M{fMV2ROW09? NFfKOJRi[3SrdnH0[ZMhWFB{QR?= M17EXVI1QTl5NEWx
HT-29  NGDnN2xHfW6ldHnvckBCe3OjeR?= M1O0ZlQxyqEQvF2= NWfRbVlOPDkEoHi= NUfDXoJnTE2VTx?= NFnRXnpi[3SrdnH0[ZMhWFB{QR?= MlvCNlQ6QTd2NUG=
SW480 M4nDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy0NOKh|ryP Mkf6NE04OiCq NVT5PHIzTE2VTx?= MlOxbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NELoV2wzPDl7N{S1NS=>
HT-29  NVfIWW9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7pOFDDqM7:TR?= Ml7yNE04OiCq MkDySG1UVw>? MX7pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 MYWyOFk6PzR3MR?=
SW480 NWq0ZYtPTnWwY4Tpc44hSXO|YYm= NWnENI5PPDEEoN88US=> MYi3JIQ> M1fJVmROW09? MWXy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi MX[yOFk6PzR3MR?=
HT-29  NUGw[nZHTnWwY4Tpc44hSXO|YYm= NUTJb4JOPDEEoN88US=> M2PmZlch\A>? M3e0Z2ROW09? NFXKcFRz\WS3Y3XzJINwdG:wb4PwbIVz\SCob4LtZZRqd25iY3HwZYJqdGm2edMg M4nMVlI1QTl5NEWx
SW480 NWfucIRkSXCxcITvd4l{KEG|c3H5 MVS0NOKh|ryP NULte2VOPDkEoHi= M37tW2ROW09? M1zlUIlv\HWlZYOgZY4h[WO2aY\heIlwdiCxZjDjZZNx[XOnIEOvOy=> MoS1NlQ6QTd2NUG=
HT-29  NHjUWmRCeG:ydH;zbZMhSXO|YYm= M4W1fVQxyqEQvF2= MlvEOFjDqGh? MoTHSG1UVw>? NE\S[IxqdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> NEG4b40zPDl7N{S1NS=>
SW480 NHzjXVFCeG:ydH;zbZMhSXO|YYm= MomyOFDDqM7:TR?= M3K3cVQ5yqCq MoDDSG1UVw>? MX;pcoR2[2W|IHPoZY5o\XNiaX6geIhmKHCqb4PwbI9zgWyjdHnvckB{fGG2dYOgc4YhWFB{QTD0ZZJo\XS| NUS1bno4OjR7OUe0OVE>
HT-29  NYLKbGVCSXCxcITvd4l{KEG|c3H5 MWG0NOKh|ryP NVzO[YdzPDkEoHi= MXnEUXNQ M4jPVYlv\HWlZYOgZ4hidmenczDpckB1cGVicHjvd5Bpd3K7bHH0bY9vKHO2YYT1d{Bw\iCSUELBJJRiemendIO= M1;yPFI1QTl5NEWx

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 410.5
Formula

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
Synonyms Coleonol

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

cAMP Signaling Pathway Map

Tags: buy Forskolin | Forskolin supplier | purchase Forskolin | Forskolin cost | Forskolin manufacturer | order Forskolin | Forskolin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID